JS
Josh Schimmer Cantor Fitzgerald Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$349M
| $3.23 | $8 |
148%
upside
| Overweight | 27 days ago |
|
2
BridgeBio Pharma
BBIO
$9.91B
| $51.83 | $95 |
83%
upside
| Overweight | 1 month ago |
|
3
Trevi Therapeutics
TRVI
$880M
| $7.23 | $25 |
246%
upside
| Overweight | 2 months ago |
|
|
CMPS
4
Compass Pathways
CMPS
$489M
| $5.10 | $6 |
18%
upside
| In-Line | 2 months ago |
|
|
CMPS
5
Compass Pathways
CMPS
$489M
| $5.10 | $12 |
135%
upside
| Overweight | 3 months ago |
|
|
SEPN
6
Septerna, Inc. Common Stock
SEPN
$630M
| $14.12 | $25 |
77%
upside
| Overweight | 3 months ago |
|
7
Ascendis Pharma
ASND
$12B
| $198.13 | $280 |
41%
upside
| Outperform | 4 months ago |
|
8
CG Oncology
CGON
$2.36B
| $30.94 | $75 |
142%
upside
| Overweight | 4 months ago |
|
9
Krystal Biotech
KRYS
$4.33B
| $149.75 | $215 |
44%
upside
| Overweight | 6 months ago |
|
10
Janux Therapeutics
JANX
$1.44B
| $23.94 | $200 |
735%
upside
| Overweight | 8 months ago |
|
11
Tourmaline Bio
TRML
$645M
| $25.10 | $25 |
0%
downside
| Overweight | 8 months ago |
|
12
ARS Pharmaceuticals
SPRY
$1.06B
| $10.69 | $30 |
181%
upside
| Overweight | 11 months ago |
|
13
Crinetics Pharmaceuticals
CRNX
$3.23B
| $34.25 | $90 |
163%
upside
| Overweight | 11 months ago |
|
14
Avidity Biosciences
RNA
$6.24B
| $48.47 | $53 |
9%
upside
| Outperform | 1 year ago |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $38.64 | $65 |
68%
upside
| Overweight | 1 year ago |
|
16
Mirum Pharmaceuticals
MIRM
$3.73B
| $74.18 | $60 |
19%
downside
| Overweight | 1 year ago |
|
17
Insmed
INSM
$30.1B
| $142.53 | $75 |
47%
downside
| Outperform | 1 year ago |
|
18
Erasca
ERAS
$420M
| $1.48 | $11 |
643%
upside
| Outperform | 2 years ago |
|
|
19
BridgeBio Pharma
BBIO
$9.91B
| $51.83 | $40 |
23%
downside
| Outperform | 2 years ago |
|
20
Neurocrine Biosciences
NBIX
$13.9B
| $140.40 | $130 |
7%
downside
| In-Line | 2 years ago |
|
21
Regeneron Pharmaceuticals
REGN
$60.1B
| $567.22 | $760 |
34%
upside
| In-Line | 2 years ago |
|
22
Zymeworks
ZYME
$1.07B
| $14.08 | $15 |
7%
upside
| Outperform | 3 years ago |
|
23
Cullinan Oncology
CGEM
$408M
| $6.91 | $55 |
696%
upside
| Outperform | 4 years ago |
|